Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue N, Seattle, WA 98109-5219, USA.
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Cell Rep Med. 2021 Oct 19;2(10):100423. doi: 10.1016/j.xcrm.2021.100423.
Host-directed therapy (HDT) is gaining traction as a strategy to combat infectious diseases caused by viruses and intracellular bacteria, but its implementation in the context of parasitic diseases has received less attention. Here, we provide a brief overview of this field and advocate HDT as a promising strategy for antimalarial intervention based on untapped targets. HDT provides a basis from which repurposed drugs could be rapidly deployed and is likely to strongly limit the emergence of resistance. This strategy can be applied to any intracellular pathogen and is particularly well placed in situations in which rapid identification of treatments is needed, such as emerging infections and pandemics, as starkly illustrated by the current COVID-19 crisis.
宿主导向治疗(HDT)作为一种对抗病毒和细胞内细菌引起的传染病的策略,正受到越来越多的关注,但在寄生虫病方面的应用却较少。本文简要概述了这一领域,并提倡将 HDT 作为一种有前途的抗疟干预策略,利用未开发的靶点。HDT 为重新利用药物提供了基础,可能会强烈限制耐药性的出现。该策略可应用于任何细胞内病原体,在需要快速确定治疗方法的情况下尤为适用,例如新发感染和大流行,当前的 COVID-19 危机就鲜明地说明了这一点。